Kidney TumorsNCT01401777
Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study
An observational study of Kidney Tumors, run by Philips Healthcare at 1 site in United States.
Trial summary
The objective of this study is to assess and quantify any differences between assisted (using real-time visualization of tracked cryo-probes) and unassisted cryoablation procedures using pre-procedure CT scans or CT fluoroscopy with respect to: Primary Endpoint: "TRE" Target Registration Error (distance between… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Kidney Tumors
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2014to Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Promary Care Clinic
Who may be able to join
- Has had a pre-operative CT/MRI scan performed and will be undergoing an ablation procedure of the kidney;
- Is over the age of 18;
- Has the ability to understand and the willingness to sign a written informed consent form, and complies with the protocol;
- Has the ability to follow procedural instructions, including, but not limited to, holding their breath and remaining reasonably motionless during the procedure.
Who cannot join
- 1. Was precluded from an ablation procedure based on standard ablation exclusions; 2. Has an adhesive allergy (due to the application of active fiducials with adhesive backing); 3. Has a pacemaker or automatic implantable cardiac defibrillator; 4. Has a gross body weight above the procedural table limit (typically > 170 kg); 5. Is pregnant
- -
Trial locations and contacts
1 site in 1 country.
About this study
The objective of this study is to assess and quantify any differences between assisted (using real-time visualization of tracked cryo-probes) and unassisted cryoablation procedures using pre-procedure CT scans or CT fluoroscopy with respect to:
Primary Endpoint:
Read more
- "TRE" Target Registration Error (distance between "virtual" needle position (tracking data) and the actual needle position (CT confirmation scan))
Secondary Endpoints
- Accuracy of needle targeting - The vector of each needle insertion (The initial vector allows us to project the path to the pre-defined target. If the initial entry point is not ideal, the path to the target will need adjustment) Based on a two-sample t-test (significance level of 0.05, two-tailed), the study has 89% power to detect a difference of 2mm in accuracy between the two treatment groups (assuming a standard deviation of 1.9mm).
- Measure time difference between assisted and unassisted procedure
Read the detailed description
The objective of this study is to assess and quantify any differences between assisted (using real-time visualization of tracked cryo-probes) and unassisted cryoablation procedures using pre-procedure CT scans or CT fluoroscopy. To assess this, physicians will perform ablation procedures with and without the Percu Nav device. Data will be collected on the angle of needle entry unassisted and then assisted by PercuNAv to determine if the added imaging information modifies the physician's needle approach.
Each patient will have a pre-procedure CT image set of the area of interest acquired. The patient will be scanned in the same position that the ablation will be performed in, although not requisite. Sterile registration patches will be applied to the patient's skin around the area of interest prior to the scan, ensuring that suitable windows are left available for needle entry. The patient will undergo these pre-procedural scans as part of the usual clinical evaluation of the lesion to undergo ablation. The scans may be acquired with or without contrast, at the discretion of the physician.
Control group: The physician will perform the procedure using the standard of care method (CT only), without the additional information being recorded by the PercuNav device. The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again. At the end of the procedure a verification CT scan will be taken with the needle in place and sent to the PercuNav.
Percu Nav group: The physician will perform the procedure using the standard of care procedure with the additional information displayed and recorded by the PercuNav device (CT and PercuNav). The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will be shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure a verification CT scan will be taken (as is part of the regular standard of care procedure) with the needle in place and sent to the PercuNav.
The outcome measures that will be evaluated in the groups include:
- Accuracy - The distance between the "virtual" needle position (tracking data) and the actual needle position (CT confirmation scan)), where applicable (TRE)
- Time to reach a clinically acceptable target in the tumor
- The total procedure time
- Accuracy of needle targeting - The vector of each needle insertion (The initial vector allows us to project the path to the pre-defined target. If the initial entry point is not ideal, the path to the target will need adjustment)
- Conditions
- Kidney Tumors
- Keywords
- Kidney Tumors, Cryoablation, Biopsy
- Medical subject headings
- Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Control, No PercuNav | Patient having procedure without PercuNav Guidance information | |
| PercuNav aided procedure | Biopsy procedure aided with use of PercuNav |
What is being measured
The primary outcome is the main question the study is designed to answer.
Target Registration Error
"TRE" Target Registration Error (distance between "virtual" needle position (tracking data) and the actual needle position (CT confirmation scan))
Measured: 24 hrs
Secondary outcomes (1)
Accuracy of needle targeting
The vector of each needle insertion (The initial vector allows us to project the path to the pre-defined target. If the initial entry point is not ideal, the path to the target will need adjustment)
Measured: 24 hrs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2011 (estimated)
- Study startDec 2014
- Primary completionMay 2015 (estimated)
- Study completionDec 2015 (estimated)
Why it stopped: On hold pending product development
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Philips Healthcare
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01401777
- Sponsor's protocol ID
- 2010_CRYO_V7
- Status last verified
- Apr 2021
- First submitted
- 21 Jul 2011
- Last updated
- 27 Apr 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study
- ClinicalTrials.gov ID
- NCT01401777
- Acronym / sponsor ID
- 2010_CRYO_V7
- Conditions
- Kidney Tumors
- Keywords
- Kidney Tumors, Cryoablation, Biopsy
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: On hold pending product development
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Philips HealthcareIndustry (pharma, biotech, devices)
- Study start
- Dec 2014
- Primary completion
- May 2015 (estimated)
- Study completion
- Dec 2015 (estimated)
- First posted
- 25 Jul 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to assess and quantify any differences between assisted (using real-time visualization of tracked cryo-probes) and unassisted cryoablation procedures using pre-procedure CT scans or CT fluoroscopy with respect to:
Primary Endpoint:
- "TRE" Target Registration Error (distance between "virtual" needle position (tracking data) and the actual needle position (CT confirmation scan))
Secondary Endpoints
- Accuracy of needle targeting - The vector of each needle insertion (The initial vector allows us to project the path to the pre-defined target. If the initial entry point is not ideal, the path to the target will need adjustment) Based on a two-sample t-test (significance level of 0.05, two-tailed), the study has 89% power to detect a difference of 2mm in accuracy between the two treatment groups (assuming a standard deviation of 1.9mm).
- Measure time difference between assisted and unassisted procedure
Detailed description
The objective of this study is to assess and quantify any differences between assisted (using real-time visualization of tracked cryo-probes) and unassisted cryoablation procedures using pre-procedure CT scans or CT fluoroscopy. To assess this, physicians will perform ablation procedures with and without the Percu Nav device. Data will be collected on the angle of needle entry unassisted and then assisted by PercuNAv to determine if the added imaging information modifies the physician's needle approach.
Each patient will have a pre-procedure CT image set of the area of interest acquired. The patient will be scanned in the same position that the ablation will be performed in, although not requisite. Sterile registration patches will be applied to the patient's skin around the area of interest prior to the scan, ensuring that suitable windows are left available for needle entry. The patient will undergo these pre-procedural scans as part of the usual clinical evaluation of the lesion to undergo ablation. The scans may be acquired with or without contrast, at the discretion of the physician.
Control group: The physician will perform the procedure using the standard of care method (CT only), without the additional information being recorded by the PercuNav device. The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again. At the end of the procedure a verification CT scan will be taken with the needle in place and sent to the PercuNav.
Percu Nav group: The physician will perform the procedure using the standard of care procedure with the additional information displayed and recorded by the PercuNav device (CT and PercuNav). The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will be shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure a verification CT scan will be taken (as is part of the regular standard of care procedure) with the needle in place and sent to the PercuNav.
The outcome measures that will be evaluated in the groups include:
- Accuracy - The distance between the "virtual" needle position (tracking data) and the actual needle position (CT confirmation scan)), where applicable (TRE)
- Time to reach a clinically acceptable target in the tumor
- The total procedure time
- Accuracy of needle targeting - The vector of each needle insertion (The initial vector allows us to project the path to the pre-defined target. If the initial entry point is not ideal, the path to the target will need adjustment)
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control, No PercuNav | – | –Patient having procedure without PercuNav Guidance information |
| PercuNav aided procedure | – | –Biopsy procedure aided with use of PercuNav |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Promary Care Clinic
Key inclusion criteria (4 listed)
- Has had a pre-operative CT/MRI scan performed and will be undergoing an ablation procedure of the kidney;
- Is over the age of 18;
- Has the ability to understand and the willingness to sign a written informed consent form, and complies with the protocol;
- Has the ability to follow procedural instructions, including, but not limited to, holding their breath and remaining reasonably motionless during the procedure.
Key exclusion criteria (2 listed)
- 1. Was precluded from an ablation procedure based on standard ablation exclusions; 2. Has an adhesive allergy (due to the application of active fiducials with adhesive backing); 3. Has a pacemaker or automatic implantable cardiac defibrillator; 4. Has a gross body weight above the procedural table limit (typically > 170 kg); 5. Is pregnant
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Target Registration Error
Time frame: 24 hrs
"TRE" Target Registration Error (distance between "virtual" needle position (tracking data) and the actual needle position (CT confirmation scan))
1 secondary outcome
Accuracy of needle targeting
Time frame: 24 hrs
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2021.
Related trials for Kidney Tumors
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingObservational study
Federated Learning in Renal Tumor Model
Renal Tumors
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Active, not recruiting
App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
RecruitingPhase 2/3
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Tumors, run by Philips Healthcare at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 27 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Target Registration Error (time frame: 24 hrs). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2021.